Stay updated on Lintuzumab-Ac225 in Older AML Patients Clinical Trial
Sign up to get notified when there's something new on the Lintuzumab-Ac225 in Older AML Patients Clinical Trial page.

Latest updates to the Lintuzumab-Ac225 in Older AML Patients Clinical Trial page
- Check4 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, and a 'Back to Top' feature has been added.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, along with a comprehensive list of drug information, particularly various chemical compounds and medications. However, many specific medical topics and related resources have been removed.SummaryDifference5%
- Check25 days agoChange DetectedThe web page now includes information about a Phase I trial of alpha-particle immunotherapy involving 225Ac-lintuzumab and low-dose cytarabine for patients aged 60 or older with untreated acute myeloid leukemia.SummaryDifference1%
- Check33 days agoChange DetectedThe page has removed a significant clinical trial description related to a specific treatment for acute myeloid leukemia, which may impact the understanding of available therapies for patients. Additionally, the version number has been updated from v2.16.11 to v2.16.12.SummaryDifference1%
- Check40 days agoChange DetectedThe web page has been updated to version 2.16.11, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to Lintuzumab-Ac225 in Older AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lintuzumab-Ac225 in Older AML Patients Clinical Trial page.